New Oral Pill Shows Promising Results for Lupus in Global Phase 2 Trial

For the many people living with lupus, flares can be unpredictable and exhausting, affecting the skin, joints, kidneys, and more. A new oral medication called enpatoran is offering real hope: results from the global WILLOW phase 2 clinical trials, published in The Lancet and Lancet Rheumatology in May 2026, show that this once-daily pill is highly effective for lupus patients with skin involvement and shows encouraging signs of managing the disease throughout the body.

To understand why enpatoran works, it helps to know a little about how lupus starts. The immune system has proteins called Toll-like receptors (TLR7 and TLR8) that normally act as alarm systems, sensing invaders and triggering inflammation to fight them off. In lupus, these alarms get stuck in the on position, causing the immune system to mistakenly attack the body's own tissues. Enpatoran is designed to flip those switches back to off, targeting the root cause of inflammation rather than just dampening the immune system broadly.

The WILLOW trial was divided into two patient groups. The first group, cohort A, focused on patients with skin-dominant lupus (cutaneous lupus erythematosus). Results here were striking: over half of patients taking enpatoran achieved clear or nearly clear skin by the end of the study, and some saw improvement within just two weeks of starting treatment. Patients on the highest dose experienced a 72 percent improvement in skin symptoms, compared to 44 percent for those on placebo.

The second group, cohort B, included patients with systemic lupus erythematosus, the form that affects multiple organs throughout the body. While this part of the trial did not meet its specific statistical threshold for a dose-response relationship, the clinical signals were still meaningful: 50 to 58 percent of patients improved, compared to only 39 percent on placebo. The drug was especially effective for patients with elevated blood inflammation markers or those requiring high doses of steroids to keep symptoms under control.

Professor Eric Morand, the study's lead researcher and Head of the Rheumatology Group at Monash Health in Australia, highlighted another important finding: blood tests confirmed that enpatoran consistently lowered interferon levels, a key protein that drives lupus progression. When patients stopped taking the medication, interferon levels returned to baseline, confirming the drug was directly controlling the biological switch and not causing broader immune disruption.

Safety was also reassuring across all doses tested. The most common side effects were mild, including headaches, minor digestive upset, and common cold symptoms. There were no unexpected safety concerns, and serious adverse events were rare and similar in frequency to those seen in the placebo group.

Enpatoran is now moving forward into Phase 3 clinical trials, which will more definitively establish how the drug can be used as a daily treatment for people living with lupus. For patients who have struggled with the side effects of traditional immunosuppressants or found existing treatments insufficient, a well-tolerated targeted oral therapy could be genuinely life-changing.